ArticleMetabolic brain disease2026
Neuroprotective effects of Premna integrifolia nano-phytosomes in haloperidol-induced Parkinson's rat model: A computational-guided Olivil nanoformulation delivery approach.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) is an age-associated neurodegenerative disorder. While allopathic treatments offer symptomatic relief, they are often associated with side effects and reduced long-term efficacy. Hence, there is a need to bridge the gap between allopathic therapies, plant bioactives and optimized delivery systems for effective neurodegenerative disease Parkinsonism management. In contrast, plant-based therapies such as Premna integrifolia L. offer multifaceted mechanisms, enhanced bioavailability through nanophytosome delivery, blood-brain barrier permeability, and cost-effectiveness. This study aimed to evaluate, characterize, and optimize nanophytosome-loaded P. integrifolia in a haloperidol-induced PD model. Hydroalcoholic extract (HEPI, 250 mg/kg), phytosomal formulation (PHYPI, 250 mg/kg), and fraction (FPI, 100 mg/kg) were administered over 36 days. In silico molecular docking and simulations identified olivil as a potent constituent with high binding affinity to GRIA2 and ADRB2, surpassing Levodopa. Phytosomes were prepared using thin-film hydration and characterized via particle size, PDI, zeta potential, SEM, TEM, FTIR, and LC-MS. In vitro assays evaluated total phenolic/flavonoid content, oxidative stress markers (SOD, GSH, MDA), protein and dopamine levels, and inhibition of AChE, BChE, and MAO-B. In vivo assessments included behavioral tests (catalepsy, actophotometer, balance beam, rotarod) and histopathological analysis of the hippocampus and cortex. PHYPI250 significantly improved motor performance and elevated dopamine levels, while reducing oxidative stress. Olivil-GRIA2 complexes showed enhanced stability with up to five hydrogen bonds. Pro-inflammatory cytokines IL-6 and TNF-α were markedly suppressed. Enzymatic assays showed significant inhibition of AChE, BChE, and MAO-B. Histological evaluation showed preserved neuronal integrity in CA1 and CA3 regions with minimal degeneration. P. integrifolia phytosomes exhibit promising therapeutic potential in PD through antioxidant, anti-inflammatory, and neuroprotective mechanisms. Olivil demonstrates superior molecular binding and stability.
Indexed as
Identifiers
41874857What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.